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Introduction {#sec1}
============

Protein ubiquitination refers to ubiquitin conjugation at a target substrate through three enzymes, including ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin protein ligase (E3), and mainly results in degradation of a specific substrate ([@bib21]). It is one of the most prevalent post-translational modifications in eukaryotic cells ([@bib26]). Dysregulations of ubiquitination will induce serious diseases, such as cancer ([@bib12], [@bib17]). During protein ubiquitination, E3s play a key role by specifically recognizing the target substrates. Given the specificity and diversity, E3s are regarded as potential therapeutic targets in cancer ([@bib2]). However, apart from several well-defined E3s, e.g., MDM2 ([@bib19]) and NEDD4 ([@bib32]), most of them remain poorly characterized, making it a great challenge to fully understand the ubiquitination system.

Typically, substrates for E3s are discovered by biochemical experiments (e.g., two-hybrid screen or co-immunoprecipitation) in a case-by-case manner ([@bib4], [@bib16]), which are commonly time- and resource-consuming. Recently, some high-throughput methods ([@bib27], [@bib33]) have been utilized on ESI recognition. However, the screened results are still mixed with plenty of false discoveries, and proteome-wide ESI identifications are still far behind. It is indispensable to build effective computational methods to assist ESI recognition. A platform of UbiBrowser ([@bib15]) has been constructed to predict ESIs, providing references for deciphering a proteome-wide ESI network. However, it mainly depends on mechanism-agnostic enrichment of pairwise protein features among known E3-substrate pairs, overlooking the expression or functional correlations between E3s and substrates. In contrast to the limited knowledge of E3-substrate interactome, extensive omics data are available, owing to the efforts on collection and organization of high-throughput biological data by public repositories, like The Cancer Genome Atlas (TCGA, [http://cancergenome.nih.gov/](https://cancergenome.nih.gov/){#intref0015}) ([@bib3]) and Clinical Proteomic Technology Assessment for Cancer (CPTAC, <https://cptac-data-portal.georgetown.edu/cptacPublic/>) ([@bib6]). They have been widely employed in functional description of cancer-driving factors or interactions ([@bib30], [@bib31]). Association-centric heuristic methods are commonly the optimal option for omics-based analysis ([@bib25], [@bib28]), and functional related or interacting components can be identified. However, given the reversibility and dynamics of ubiquitination, it is still unclear whether E3-substrate interaction (ESI) can be correctly described by omics-based associations. In addition, progressively accumulated biological knowledge, like the annotated pathways in Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@bib13]) and experimentally verified protein-protein interaction (PPI) records in BioGrid ([@bib5]), provide an alternative way to create mechanistic descriptions on ESIs.

Here, we put forward to characterize and predict ESIs in an integrative way. It turns out that integrating omics (especially proteomics data) with network or pathway information can help distinguish ESIs from various negative categories (even indirect regulating relations). A case study on leucine-rich repeat family of F box (FBXL) proteins demonstrated that our evaluations outperformed both the UbiBrowser and a proteomics-based approach. Moreover, we portrayed a cancer-oriented ESI landscape by identifying potential ESIs for cancer hallmark proteins. In addition, to facilitate the utility of our model, both confirmed and potential ESIs along with their association features were distributed on a website (<http://www.esinet.dicp.ac.cn/home.php>).

Results {#sec2}
=======

Workflow of a Comparative Characterization on ESIs {#sec2.1}
--------------------------------------------------

We developed a computational model for both describing and predicting ESIs by integrating omics with network and pathway ([Figure 1](#fig1){ref-type="fig"}, see also [Transparent Methods](#mmc1){ref-type="supplementary-material"}). First, previously reported ESIs were collected as a positive reference dataset (PRD, [Table S1](#mmc2){ref-type="supplementary-material"}), whereas three negative reference datasets (NRDs) covering randomly combined E3s and proteins ("E3-random," [Table S2](#mmc3){ref-type="supplementary-material"}), non-ESI PPIs ("Other PPIs," [Table S3](#mmc4){ref-type="supplementary-material"}), and pairwise E3-indirect regulatory proteins ("E3-Indirect," [Table S4](#mmc5){ref-type="supplementary-material"}) were prepared as control ([Figure 1](#fig1){ref-type="fig"}A). For both PRD and NRDs, multidimensional association features between two proteins were calculated by integrating omics ([Figure 1](#fig1){ref-type="fig"}B), networks ([Figure 1](#fig1){ref-type="fig"}C), and pathways ([Figure 1](#fig1){ref-type="fig"}D). Then, specific ESI association patterns were recognized by comparing ESIs with three categories of NRDs. Finally, a prediction model was constructed through a weighted ensemble of three types of random forest classifiers (RFs) ([Figure 1](#fig1){ref-type="fig"}E).Figure 1Workflow of a Comparative Characterization on ESIs(A) The association patterns of ESIs were obtained by comparison between positive and negative reference datasets, where three different negative reference datasets (NRDs) were prepared for comprehensiveness.(B) Omics-based associations. The Spearman correlations between E3s and substrates were calculated based on both transcriptomics and proteomics.(C) Network-based associations. The ESIs were mapped onto three networks including one PPI network and two co-expression networks constructed, respectively, based on transcriptomics and proteomics data. The associations were calculated from the shared neighbors on the networks.(D) Pathway-based associations. Pathways are taken as mediators between E3 and substrates, and the pathway-based association evaluates whether one E3 is tightly related with the pathways their substrates belong to, or vice versa.(E) Diagram of ESI prediction model. It was an ensemble of three types of random forest (RF) classifiers trained with different categories of NRDs.See also [Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc5){ref-type="supplementary-material"}.

Constructing an ESI Network {#sec2.2}
---------------------------

Initially, an ESI network composed of 1,806 previously reported ESIs involving 300 E3s and 1,089 substrates was constructed to describe the complex relations between E3s and substrates ([Figure 2](#fig2){ref-type="fig"}A). Similar to other biological networks ([@bib10], [@bib20]), it exhibited an approximate scale-free topology ([@bib1]) (linear model fitting R2 index = 0.78). Most hubs in the ESI network were E3s; they had significantly higher (p value = 4.07 × 10^−7^ based on t test) degrees than substrates, suggesting that a large number of substrates can be recognized by the same E3s. However, when mapping onto the global PPI network, such difference disappeared (p value = 0.9634 by t test); E3s and substrates exhibited similar degree distribution and their degrees were much higher than those on the ESI network ([Figure 2](#fig2){ref-type="fig"}B), emphasizing that the impacts rendered by ubiquitination may be spread to various processes by non-ESI interactions. Besides, a cancer hallmark subgraph ([Figure 2](#fig2){ref-type="fig"}C) was extracted. On this subgraph, nodes belong to genes recorded in the "Catalogue of somatic mutations in cancer" (COSMIC) ([@bib8]) and edges are annotated with the ubiquitinated consequences of substrates. It suggests that a large fraction of the reported ESIs will lead to degradation of substrates. Some E3s (e.g., BRCA1 and KEAP1) are tumor suppressors; their mutations might induce the accumulation of carcinogenic substrates (e.g., AKT, IKK-β, and JAK2), which will promote the development of cancer and affect key signaling pathways, such as AKT or nuclear factor (NF)-κB signaling pathway, confirming that ubiquitination can affect cancer development and progression in alternative ways. To be more comprehensive, further refining of the ESI network is indispensable.Figure 2ESI Network(A) An ESI network. E3s (red) and their corresponding substrates (yellow) are connected as edges, where green nodes stand for proteins acting as both E3s and substrates.(B) Degree distribution of E3s (red bars) and substrates (blue bars) on the ESI network (horizontal axis) and the global PPI network (vertical axis). Centers of boxes represent median values. Bottom and top bounds of boxes represent 25th and 75th percentiles.Whiskers mark 1.5 times of the interquartile range(C) Cancer hallmark ESI subgraph. Node borders were colored according to their functions in cancer; blue stands for tumor suppressor gene (TSG), red stands for oncogene, orange represents genes with both functions, whereas the functions of gray-border ones are still unclear. The edge color represents the ubiquitinated consequence of substrates; blue stands for degradation, whereas red refers to activity change or other non-degradation effects. Nodes are labeled with the corresponding gene symbols of proteins.See also [Table S1](#mmc2){ref-type="supplementary-material"}.

Omics-Based Associations Alone Are Not Capable of ESI Recognition {#sec2.3}
-----------------------------------------------------------------

Proteomics data offer the most direct resource to capture the expression relevance between E3s and substrates, given that ESIs often results in substrate degradation. In addition, as ubiquitination is also involved in transcription regulation ([@bib11]), transcriptomics data were also employed to estimate transcriptional associations (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Notably unexpected, E3s and substrates were not negatively correlated in both mRNA and protein levels ([Figure 3](#fig3){ref-type="fig"}A, median levels for ESIs were all near zero). However, when compared with NRDs, ESIs exhibited differences in both omics: ESIs showed higher correlations than "E3-random" cases on average ([Figure 3](#fig3){ref-type="fig"}A). "Other PPIs" were more mutually correlated than ESIs; indirect regulations were similar with ESIs in terms of proteomics, but differences emerged in terms of transcriptomics. Still, more features are required because the slight differences make it difficult to separate ESIs from other possibilities.Figure 3Comparative Association Profiles of ESIs(A) Omics-based associations. Different colors in the box plots represent different datasets. PCT refers to proteomics-based correlations between two proteins in tumor tissues. Three different forms of transcriptomics-based associations were calculated. RCT/RCN means the mRNA correlations in tumor/normal tissues; RCF refers to two proteins\' correlations in terms of the fold change on mRNA of tumor tissues relative to matched normal tissues.(B) Network-based associations. Five features were calculated: CNR.PPI, CNR.CXNR, and CNR.CXNP refer to the common neighbor rate (CNR) between two proteins in the PPI network, mRNA co-expression network, and protein co-expression network respectively; CCR.PPI/CCP.PPI stands for the CNR between co-expressed factors (mRNAs/proteins) in PPI network.(C) Pathway-based associations. WCR/WCP evaluates the transcriptomics/proteomics-based correlations between E3 and the pathways their substrates belong to, whereas WCRS/WCPS estimates the correlations between E3s′ pathways and substrates based on transcriptomics/proteomics.(D) Permutation test on each form of pathway associations. WCRP, WCRSP, WCPP and WCPSP respectively represent the permutation test based P-values obtained for WCR, WCRS, WCP and WCPS. Data distributions for A-D are all discribed by box-plots. Centers of boxes represent median values. Bottom and top bounds of boxes represent 25th and 75th percentiles. Black lines mark 1.5 times of the interquartile range. Dots represent points falling outside this range.(E) The AUROCs of knn-classifiers trained based on each single feature. The gray bars stand for standard deviation of AUROCs for five repetitive classifiers. Performances of classifiers based solely on omics were only around 0.5, but inclusion of network and pathway knowledge improved the performance. Statistical significance (p \< 0.01, Wilcoxon test) for difference between each kind of NRDs and ESIs was marked by \*.See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.

E3s and Substrates Share Neighbors on PPI Network but Lack Connections on Co-expression Networks {#sec2.4}
------------------------------------------------------------------------------------------------

Omics-based associations simply investigated on the "one-to-one" expression relations, ignoring the fact that cascades of other proteins also take part in the ubiquitination process. Consequently, three network systems were applied to measure the relations between E3s and substrates systematically (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). As a result, ESIs and NRDs showed significantly different distributions on the network-based associations ([Figure 3](#fig3){ref-type="fig"}B). No matter on which kind of network, the average correlations of ESIs were significantly (p value\<0.01) less than "Other PPIs." On the PPI network, E3s and substrates are more likely to be connected by common neighbors than "E3-random" or "E3-indirect" ([Figure 3](#fig3){ref-type="fig"}B, CNR.PPI). However, this tendency was changed on the co-expression network; especially on the protein co-expression network ([Figure 3](#fig3){ref-type="fig"}B, CNR.CXNP), the ESIs were less connected compared with all other NRDs, even the random cases, reflecting that the ESIs interrupt the expression correlations despite the probably transient and dynamic properties. When the co-expression networks and PPI network were integrated, the profile ([Figure 3](#fig3){ref-type="fig"}B, CCR.PPI and CCP.PPI) was similar with that based on PPI network. The network-based associations can assist to differentiate the substrates of E3s from indirect or random situations in a relatively more accurate manner than the omics-based associations.

Pathway-Based Associations Improve ESI Discriminability and Provide Hypothesis on Their Upstream or Downstream Processes {#sec2.5}
------------------------------------------------------------------------------------------------------------------------

As a special kind of bionetworks, a pathway refers to a cascade of molecular interactions with interdependent functions. A total of 306 human pathways in KEGG ([@bib13]) were considered as intermediary to examine the functional associations between E3s and substrates (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). With regard to mRNA-based pathway associations (i.e., WCR, WCRS), ESIs only exhibited modest higher associations than "E3-random" and "E3-Indirect" ([Figure 3](#fig3){ref-type="fig"}C); however, permutation tests on these associations indicated that specificities (i.e., WCRP, WCRSP) of the pathway-based associations of ESIs were much higher than those of the others ([Figure 3](#fig3){ref-type="fig"}D). It suggests that although E3s were not highly correlated or co-expressed with their substrates compared with random or indirect regulatory cases in mRNA level ([Figures 3](#fig3){ref-type="fig"}A and 3B), they may be closely related with the other members of the pathways their substrates belong to, or vice versa. Proteomic level presented different tendency; ESIs exhibited lower associations than all three NRDs on average, but the specificities were higher than "E3-random" and "E3-Indirect." The "Other PPIs" exhibited both considerably higher pathway associations and permutation scores than ESIs. It is probably a consequence of the degradation effect or dynamic nature of ESIs. Moreover, the pathway-based associations promoted to discriminate ESIs from NRDs; some of them ([Figure 3](#fig3){ref-type="fig"}E, WCP, WCR, WCPP, WCPSP) even rendered better performances than network-based features, especially in distinguishing ESIs from "Other PPIs."

The pathway-based associations can also capture which pathway was highly correlated with an ESI (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). For example, pathways, like cell cycle ([@bib23], [@bib35]), p53 signaling pathway ([@bib14], [@bib34]), and transforming growth factor-β signaling pathway ([@bib9]), all of which have been confirmed as ubiquitination-mediated pathways, were highly correlated with the E3s in proteomics, and a large fraction of substrates can be located on these pathways ([Figure S1](#mmc1){ref-type="supplementary-material"}), similar results were observed in the transcriptomics-based pathway associations ([Figure S2](#mmc1){ref-type="supplementary-material"}), implying that our analysis might provide some hypotheses on the upstream or downstream processes for certain ESIs by referring to the highly correlated pathways.

Pan-Cancer Analysis Show Concordance on the E3-Substrate Association Patterns {#sec2.6}
-----------------------------------------------------------------------------

The analyses above utilized omics data from Breast Invasive Carcinoma (BRCA) in TCGA. To be more comprehensive, we asked whether the ESI association patterns were consistent across different cancers. We recalculated the features based on additional 10 cancers. Parallel analyses based on distinct cancers manifested that the differential trends between ESIs and NRDs on most available features were consistent with those shown in BRCA ([Figures 3](#fig3){ref-type="fig"}A--3D and [S3](#mmc1){ref-type="supplementary-material"}A--S3J). The concordance also indicates that the multi-omics data in TCGA can be applicable to gain insights into biological mechanism in a more universal manner, even though they are originally cancer oriented.

Classification Models Based on the Multidimensional Associations Perform Well in Discriminating ESIs from NRDs {#sec2.7}
--------------------------------------------------------------------------------------------------------------

The considerable differences between ESIs and NRDs in the multidimensional association space prompt us to construct a classification model wherein three types of reverse-feature-reduction based random forest classifiers (RFE-RFs) were combined to identify ESIs ([Figure 4](#fig4){ref-type="fig"}A, see also [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The performance was quantified by the area under the receiver operating characteristic curve (AUROC). The classification model showed a satisfying and stable performance ([Figures 4](#fig4){ref-type="fig"}B--4D), especially when "E3-random" and "Other PPIs" categories (average AUROCs around 0.87 and 0.85, respectively) were taken as negatives, whereas the performance was somewhat declined for "E3-Indirect" (average AUROCs around 0.78). The observation indicated it is more difficult to separate true substrates from indirect regulatory proteins than other negative cases. For different types of RFE-RFs, features like CNR.PPI, WCR, and WCP ([Figure 4](#fig4){ref-type="fig"}E) were consistently selected for all classifiers, further confirming the importance of network and pathway-based associations.Figure 4Classification Models for Distinguishing ESIs from NRDs(A--D) (A) Sample assignment for five rounds of crossover validations and an independent validation. (B--D) Performance of three types of RFE-RFs. The same ESIs were used as positive samples, whereas "E3-random" (B), "Other PPIs" (C), and "E3-Indirect" (D) pairs were taken as negatives. The horizontal and vertical axes represent the number of selected features and the corresponding average AUROC got from a 10-fold crossover validation. For each type of RFE-RFs, five classifiers were constructed by replacing negative samples.(E) Selected features for each classifier in (B--D).(F) Density plot of the predicted probabilities across four types of samples in the independent validation dataset.(G) Threshold selection for positive predictions. Performances under different thresholds (th) were evaluated by F3-score.(H) Histogram of positively predicted samples across different categories of samples in the independent validation.See also [Table S5](#mmc1){ref-type="supplementary-material"}.

Moreover, ESIs were predicted with significantly higher probabilities than all three types of NRDs ([Figure 4](#fig4){ref-type="fig"}F). Both crossover and independent validations show that our model can help separate true and false ESIs. Although false-positives still existed, the misclassification rate was significantly reduced by inclusion of three negative categories. In general, random cases are always chosen as negative controls in interactome prediction, based on which the classifier generated much more false-positives (24% of "E3-Random," 83% of "Other PPIs," and 62% of "E3-indirect" were misclassified as ESIs, [Figure 4](#fig4){ref-type="fig"}H). Similar conditions were observed when only "Other PPIs" or "E3-Indirect" was taken as the control. However, when three types of classifiers were integrated, the false discovery rate was significantly reduced, with 73% ESIs being accurately predicted under the threshold of 0.48 ([Figures 4](#fig4){ref-type="fig"}G and 4H), whereas only 15% "E3-Random," 31% "Other PPIs," and 30% "E3-indirect" being misclassified.

We also trained the models by omics data from other cancers ([Table S5](#mmc1){ref-type="supplementary-material"}). We observed that models trained based on ovarian serous cystadenocarcinoma(OV) and BRCA, where both transcriptomics and proteomics data were available, obtained better performance than others with only transcriptomics data, confirming the importance of multi-omics integration. As data of BRCA were more comprehensive than OV (only 155 ESIs can be assigned with both omics), we mainly utilized data from BRCA in the following study.

Prediction and Validation on Potential Substrates of FBXL Family {#sec2.8}
----------------------------------------------------------------

To further estimate the model quality, we applied it on the FBXL proteins, of which certain post-transcriptional modifications are often required for the substrates ([@bib24]). In particular, to avoid circularity of training and predicting samples, we reconstructed the classification model ([Figure S4](#mmc1){ref-type="supplementary-material"}) by removing known ESIs of FBXLs from the training process. Both known and potential substrates were identified by our model. Considering 89 confirmed ESIs of FBXLs, 39 pairs that can be assigned with the multidimensional features were calculable by our model, and 27 of the 39 (69%) cases were correctly recalled, whereas only 13 among the 39 cases were predicted by UbiBrowser ([Table S6](#mmc6){ref-type="supplementary-material"}).

Multiple FBXLs were predicted to target on substrates belonging to the pathways of cell cycle, ribosome biogenesis in eukaryotes, ubiquitin-mediated proteolysis, and spliceosome ([Figures 5](#fig5){ref-type="fig"}A and 5B). The mostly influenced pathway is the cell cycle pathway, where multiple known substrates like MYC, SMAD4, and CCNE1 were correctly linked to SKP2, and other unreported ones like CCNA2 and CDK1 were predicted to be recognized by FBXL3, FBXL6, and FBXL10, indicating the potential cross-regulatory mechanism on the cell cycle pathways by FBXLs. This is consistent with the fact that F box proteins play key roles in cell cycle regulation ([@bib35]).Figure 5Evaluations on Substrates of FBXL Family E3s(A and B) Known (red edge) and predicted (gray edge) ESIs for FBXLs. The meaning of node colors and shapes is the same as in [Figure 2](#fig2){ref-type="fig"}. For clarity, only the high-confidence substrates (with a predicted probability higher than 0.65 and ranked within top-20 for corresponding FBXL) were shown. (A) A large part of the predicted ESIs are mapped onto cell cycle pathway by pathway-based associations. (B) In addition to substrates on the cell cycle pathway, the FBXLs were also predicted to target on other substrates across different pathways.(C) Boxplot of the predicted results on candidate ESIs. The putative ESIs identified by PAC (orange box) were observed with significant higher probabilities than the remaining ones (green box). \*p \< 0.01 (Wilcoxon test, two sided, unpaired).See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S6](#mmc6){ref-type="supplementary-material"}.

To test on the quality of our model, we compared our predictions to a proteomics-based experimental study ([@bib27]), where a well-designed parallel adaptor capture (PAC) proteomic method was applied to discriminate putative substrates for FBXLs. Among all the candidate pairs we predicted, the intersection with putative ones identified by PAC show significant (Wilcoxon test, p value = 1.036 × 10^−6^) higher probabilities than the others ([Figure 5](#fig5){ref-type="fig"}C), confirming the reliability of our model. Besides, among all 89 confirmed ESIs of FBXLs, 27 cases were correctly identified by our model, whereas only 5 and 22 can be discriminated by the PAC method and UbiBrowser, respectively ([Table S6](#mmc6){ref-type="supplementary-material"}).

Furthermore, we experimentally checked on several high-confidence substrates of SKP2 and FBXL6 (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). For SKP2, its interactions with four predicted substrates were validated, where the interaction with CCNA2 was already reported by previous studies ([@bib18]) and the other three proteins including CASP3, DDB1, and HSP90AA1 have not been discovered ([Figure 6](#fig6){ref-type="fig"}A, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B). For FBXL6, an orphan E3 without any known substrates, its interactions with five predicted substrates including CDK4, CCNA2, HSP90AA1, HSPD1, and VDAC2 were validated ([Figures 6](#fig6){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}A--S5D). Moreover, we found that FBXL6 inhibited CCNA2 and VDAC protein expression in a dose-dependent manner ([Figure 6](#fig6){ref-type="fig"}C). In addition, FBXL6 and SKP2 significantly increased both endogenous and exogenous CCNA2 protein polyubiquitylation ([Figures 6](#fig6){ref-type="fig"}D and 6E). In contrast, knockdown of FBXL6 expression by transducing shRNA_FBXL6 significantly inhibited polyubiquitylation of VDAC2 ([Figures 6](#fig6){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}E). Also, we examined CCNA2 protein levels in the presence of cycloheximide. As expected, SKP2 and FBXL6 significantly decreased the stability of CCNA2 protein ([Figures 6](#fig6){ref-type="fig"}G and 6H). These experimental results prove that our predictions can provide credible references on identification of promising ESIs.Figure 6Experimental Validations on High-Confident Predictions(A and B) Validations on interactions between substrates and FBXLs. HEK293T cells were transfected with SFB-tagged SKP2 or FBXL6. SKP2 and FBXL6 were purified with S protein beads and immunoblotted with antibodies against substrates. (A) Interactions between SKP2 and DDB1, Cyclin A2 (CCNA2), Caspase-3 (CASP3), as well as HSP90AA1 were examined. (B) Interactions between FBXL6 and CDK4, CCNA2, HSP90AA1, HSPD1, as well as VDAC2 were examined.(C) Increased FBXL6 correlates with reduced CCNA2 and VDAC2 expression. HEK293T cells were transfected with SFB-FBXL6 at different doses (0, 1, and 3 or 6 μg) for 48 h. Expression of CCNA2 and VDAC2 were analyzed by western blot.(D) FBXL6 mediated the ubiquitination of CCNA2. SFB-FBXL6 vector was transfected into HEK293T cells along with or without haemagglutinin-tagged ubiquitin (HA-Ub). Cells were cultured for 48 h, and cell lysates were probed with CCNA2 antibody.(E) FBXL6 and SKP2 mediated the ubiquitination of CCNA2. HEK293T cells were transfected with SFB-CCNA2 and HA-Ub along with Myc-FBXL6 or Myc-SKP2 for *in vivo* ubiquitination assay. CCNA2 was purified with S protein beads and ubiquitination of CCNA2 by FBXL6 and SKP2 were analyzed.(F) HA-Ub and SFB-VDAC2 were co-transfected with control or FBXL6-shRNA into HEK293T cells. Cells were treated with 20 μM MG132 for 4 h before collection. VDAC2 was purified with S protein beads and western blotted with antibodies against HA, FLAG, and FBXL6.(G) HEK293T cells were transfected with SFB-FBXL6, SFB-SKP2, along with CCNA2-V5 for *in vitro* half-life assay under 100 μg/mL of cycloheximide (CHX) treatment. Cells were collected at different time points and immunoblotted with antibodies against CCNA2 and GAPDH. S/L: short/long exposure.(H) Quantification of relative CCNA2 levels in (G) and replicated experiments were performed using ImageJ, and data are represented as mean ± SEM. \*p \< 0.05 (t test, two sided, unpaired) for the comparisons of both SKP2 and FBXL6 to empty vector (EV). The experiments were repeated three times, and the most representative image is shown.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Inferences on Potential E3s for Cancer Hallmark Proteins {#sec2.9}
--------------------------------------------------------

To be more comprehensive, the ultimate prediction model ([Figure S6](#mmc1){ref-type="supplementary-material"}) was reconstructed by incorporating all known ESIs into the training procedure. Finally, about 2,80,000 pairs of proteome-wide potential ESIs were inferred by our model. To investigate whether cancer hallmark proteins might be ubiquitinated by certain E3s (see [Table S7](#mmc7){ref-type="supplementary-material"} for all investigated E3s), candidate pairs with COSMIC-recorded proteins as substrates were retrieved. Among them, 79 pairs were predicted as high-confidence (p \> 0.75, [Figure 7](#fig7){ref-type="fig"}A) cases for cancer hallmark proteins, where 22 of them were previously revealed and another 57 were predicted (19 of them have been reported or examined in previous literatures, [Table S8](#mmc8){ref-type="supplementary-material"}). A number of crucial pathways for cancer, e.g., NF-κB signaling pathway, Notch signaling pathway, and apoptosis, were influenced by these E3s ([Figure 7](#fig7){ref-type="fig"}A). Besides, these predicted hallmark ESIs show the "multi-to-multi" relations between E3s and substrates again. This information is important for E3s that may be taken as promising therapeutic targets for cancers. It is essential to make sure that drugs targeting on certain E3s will not lead to undesirable outcomes by disturbing unexpected ESIs for the multifunctional E3s.Figure 7High-Confidence ESIs Predicted for Cancer Hallmark Substrates(A) The left side shows the highly correlated pathways by which the E3s (rows of the right-side matrix) may exert their ubiquitination effects. The right side represents the high-confidence (prob\>0.7) ESIs with cancer hallmark proteins as substrates, where the rows and columns stand for E3s and substrates, respectively.(B) Predictions for BRCA1 across different cancers.See also [Figure S6](#mmc1){ref-type="supplementary-material"}, [Tables S7](#mmc7){ref-type="supplementary-material"} and [S8](#mmc8){ref-type="supplementary-material"}.

Besides, we observed that BRCA1, a tumor suppressor with E3 activity, was also predicted as the substrate for multiple E3s when the prediction was conducted based on data of TCGA-BRCA ([Figure 7](#fig7){ref-type="fig"}A). However, some interactions were not high-confidence ones any more in other cancers ([Figure 7](#fig7){ref-type="fig"}B), implying the assumption that predicted results for mutant substrates can be cancer type specific.

Discussion {#sec3}
==========

Progressive accumulation in multi-omics data ([@bib3], [@bib6]) and prior biological knowledge ([@bib5], [@bib13]) allow for a data-driven investigation on ESIs. Here, we aimed to construct an ESI landscape and describe the association profiles between E3s and substrates by integrating different data resources.

Our study provides a glance at the association patterns of ESIs by combining multi-omics data and biological knowledge, where three types of negative control were taken into consideration. An initial scale-free ESI network composed of 1,806 reported ESIs was constructed, where plenty of cancer hallmark genes act as hubs, and the numbers of interacting substrates for different E3s vary considerably. It may suggest a general rule that some E3s are with a broad-spectrum function and that they can regulate various types of substrates, whereas the others only have effects on certain substrates. Unexpectedly, although a large fraction of ESIs will lead to substrate degradation ([Figure 2](#fig2){ref-type="fig"}C), E3s and substrates did not show significantly negative correlations in the omics-based associations ([Figure 3](#fig3){ref-type="fig"}A), suggesting that no consistent expression relation exists for ESIs and indicating the heterogeneity of ubiquitination mechanism. Nonetheless, integrating omics with network or pathway information greatly enhanced the differences between ESIs and NRDs, and the degradation effect emerged. Notably, the pathway-based associations can help identify downstream or upstream processes such as DNA replication ([@bib7]) and mammalian target of rapamycin signaling pathway ([@bib29]). The effectiveness and consistency of omics-driven association features for ESI identification also indicate the reusability of cancer omics-resources.

Different from the models utilized by UbiBrowser ([@bib15]) where only one negative category was considered, our model combined three negative categories covering "E3-random," "Other PPIs," and "E3-Indirect." Both crossover and independent validations have demonstrated the model\'s effectiveness, and the inclusion of three negative categories has significantly reduced the false discovery rate. Moreover, the false discoveries (e.g., SKP2-CUL1, FBXL19-UBE2T, [Figures 5](#fig5){ref-type="fig"}A and 5B) can be reduced further by removing E1s, E2s, and scaffold proteins in E3 complexes from candidate substrates, as most of them are already defined by studies on well-characterized E3s, like FBXW7 and MDM2. Taken together, our predictions can provide assistance on ESI recognition, but further experimental investigations are also required to confirm the interactions.

Our model also exhibits effectiveness for substrates that require certain forms of modifications before ubiquitination. Taking FBXL family as an illustration, our predictions output consistent results with a previous proteomic experimental study ([@bib27]) and with a significantly improved recall (27/89 versus 5/89). When compared with UbiBrowser, our model also showed higher recall (27/89 versus 22/89), and the superiority was even higher in terms of calculable cases (27/39 versus 13/39), suggesting the advantage of our model, especially for substrates with knowledge background. Furthermore, a number of un-reported predictions of ESIs for SKP2 and FBXL6 were validated by experimental investigations. All the above imply the effectiveness of our prediction model.

In conclusion, our study provides a data-driven way to portray the ESI landscape, offering meaningful hypothesis on the latent E3-substrate association patterns, promising ESIs or even regulatory mechanism. For convenience, a website (<http://www.esinet.dicp.ac.cn/home.php>) is developed for browsing the multi-scaled association features of confirmed (1,806 pairs) and proteome-wide predicted (about 2,80,000 pairs) ESIs. It provides a valuable resource and assistance for further studies on protein ubiquitination.

Limitations of the Study {#sec3.1}
------------------------

The data-driven prediction model\'s application scope is limited by currently available data resources, especially the proteomics data that is indispensable for most prediction-dependent multidimensional features. Although we utilized a relatively comprehensive proteomics database CPTAC wherein 10,602 proteins (about 400 E3s were included) were measured, some E3s like FBXL2, FBXL5, and FBXL22 were still not covered. We cannot calculate the multidimensional features for these items, thus lacking predictions on these E3s. As more proteomics data and network or pathway knowledge are being accumulated, we envision a continual optimization of the prediction results.

In addition, the fate of ubiquitinated substrates depends on the linkage of ubiquitin chains ([@bib22]). Although most of the reported ESIs can lead to substrate degradation by K48 or K11 linkage, ubiquitination can also induce other outcomes, like activity or stability change. Our present prediction model mainly focuses on whether there is an interaction between an E3 and a substrate; however, the linkage-dependent ubiquitinated consequence was not considered. In our future studies, we will attempt to deduce the linkage information as well.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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